MINI FUTURE SHORT - AMGEN | Real-time Bid/Ask 05:08:31 04/06/2024 pm IST | ||
| 10.96 EUR / 11.09 EUR | -0.14% |
|
| Current month | -2.13% | ||
| 1 month | -0.99% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 04/24/04 | 10.73 | -2.81% |
| 03/24/03 | 11.04 | -2.13% |
| 31/24/31 | 11.28 | -1.05% |
| 30/24/30 | 11.4 | -6.02% |
| 29/24/29 | 12.13 | +3.59% |
Delayed Quote Börse Stuttgart
Last update June 04, 2024 at 01:03 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | AMGEN INC. |
| Issuer | Morgan Stanley |
| WKN | ME6R67 |
| ISIN | DE000ME6R671 |
| Date issued | 10/01/2024 |
| Strike | 427 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 10.87 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 15.58 € |
|---|---|
| Lowest since issue | 9.72 € |
| Spread | 0.13 € |
| Spread % | 1.17% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
307.4
USD
Average target price
316.3
USD
Spread / Average Target
+2.88%
- Stock Market
- Certificates
- Certificat
